Journal scan

New cell could guide immunotherapy for lung cancer

Immune cell could predict which patients would benefit most from treatment.
Lung cancer

A newly discovered immune cell could predict which lung cancer patients would benefit most from immunotherapy treatment, according to a study.

Researchers at the University of Southampton and La Jolla Institute for Allergy and Immunology, California, found that lung cancer patients with large amounts of a particular type of immune T-cell, called tissue-resident memory T-cells, in their tumour were 34% less likely to die.

Cancer survival

The Cancer Research UK-funded study found that the cells’ behaviour also increased survival. They clustered together and ‘took up residency’ in a particular tissue, in this case the cancer tissue, to protect the patient.

These T-cells also produce other molecules that attack the tumour, meaning that the body’s immune system could be more likely to destroy cancer cells.

Immunotherapies have shown great promise in the past decade, but identifying


Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Nursing Standard
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?